In the Boardroom
Refine Search
Biotechnology
US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
Anthony Harnden has been appointed as the new chair of the UK’s Medicine and Healthcare products Regulatory Agency (MHRA). 20 November 2024
Biotechnology
Mirai Bio has announced the appointment of Jens Vogel as the company’s president and chief operating officer (COO). 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Pharmaceutical
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Biotechnology
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
Biotechnology
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
Pharmaceutical
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
Biotechnology
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Biotechnology
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Biotechnology
US biotech major Biogen revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs. 29 October 2024
Pharmaceutical
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Biotechnology
Oslo-based biotech Zelluna Immunotherapy has appointed Namir Hassan as chief executive officer, replacing Miguel Forte. 19 December 2019
Biotechnology
In a surprise move, Ipsen chief executive David Meek has quit his position at the French drugmaker to take the helm at a small gene therapy startup, FerGene. 18 December 2019
Pharmaceutical
Katy Wallace, principal consultant in the Life Sciences Practice at executive search firm, Berwick Partners, explains why the pharma industry needs diverse leadership in an Expert View piece. 10 December 2019
Pharmaceutical
US drugmaker Eli Lilly appears to have been so impressed with its newly-acquired subsidiary Loxo Oncology that it has asked it to take over the running of its oncology R&D. 5 December 2019
Pharmaceutical
A US Senate panel has all but confirmed that Stephen Hahn will be the next Commissioner of the Food and Drug Administration (FDA). 4 December 2019
Biotechnology
India's Biocon, Asia's premier biotechnology company, has named Siddharth Mittal as its new chief executive and joint managing director. 3 December 2019
Biotechnology
Vancouver, Canada-based regenerative medicine company NervGen Pharma announced the appointment of Paul Brennan as president and chief executive effective immediately. 28 November 2019
Pharmaceutical
Germany-headquartered central nervous system (CNS) specialist Neuraxpharm Group today announced the expansion of its operations in Southern Europe with the launch of Neuraxpharm Portugal. 28 November 2019
Pharmaceutical
The Office of Women’s Health (OWH), part of the US Food and Drug has announced the selection of Kaveeta Vasisht as the Associate Commissioner for Women’s Health. 27 November 2019
Biotechnology
Kite Pharma, which was acquired in 2017 by Gilead Sciences in a transaction valued at around $12 billion, announced two new additions to the company’s leadership team. 22 November 2019
Pharmaceutical
Vifor Pharma today announced the appointment of Lee Heeson as president international and a member of the executive committee as of February 1, 2020, with the news sending the Swiss drugmaker’s shares up 2.37% to 161.85 francs. 18 November 2019
Pharmaceutical
A little over five years ago, British drugmaker GlaxoSmithKline was riding high, following multiple years of strong sales and related year-on-year share price gains. 15 November 2019
Generics
US healthcare and medical devices company Abbott today announced that Miles White will be stepping down as chief executive on March 31, 2020, after a remarkable 21-year tenure, the second longest for a non-founder in today's S&P 100, according to the company. 13 November 2019
Generics
Shares in Teva Pharmaceutical Industries were up by 11% after 100 minutes of New York trading on Thursday, following the company’s presentation of its third-quarter financial results. 7 November 2019
Pharmaceutical
Swiss specialty drugmaker Santhera Pharmaceuticals this afternoon announced a strategic change to its management team with the appointment of Dario Eklund as chief executive effective December 1, 2019. 4 November 2019
Biotechnology
US therapeutic gene editing company Sangamo Therapeutics has appointed Sung Lee as executive vice president and chief financial officer, effective October 31, 2019. Mr Lee oversees finance, facilities and information technology functions for Sangamo and reports to the firm’s chief executive. 2 November 2019
Biotechnology
USA-based biotech Ovid Therapeutics has made two senior leadership changes to further build the company’s capabilities as it approaches top-line results from the pivotal Phase III NEPTUNE trial for OV101 in Angelman syndrome, expected in mid-2020. 2 November 2019
Biotechnology
Genmab, one of the world’s most notable biotech success stories of recent years, has announced that one of those who helped to drive its rapid growth is to retire. 1 November 2019
Pharmaceutical
Shares of UK developer of inhaled therapeutics Vectura Group were up more than 1% at 84.07 pence, after it announced the appointment of Will Downie as chief executive and executive director of the company, effective November 7, 2019. 29 October 2019
Pharmaceutical
Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes and Lilly USA, will retire at the end of the year after 27 years of service with the company, US pharma major Eli Lilly announced today. 23 October 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze